CD274 and ovarian carcinoma: In contrast to other solid tumors, such as NSCLC or melanoma, in ovarian cancer, surface PD-L1 expression has not been proven as a reliable biomarker to select patients for anti-PD-1/PD-L1 therapy and targeting the PD-1/PD-L1 signaling has produced disappointing results [106].